News | September 17, 2014

Pediatric Brain Tumor Patient From the U.K. Undergoes First Treatment of Proton Therapy

After controversial withdrawal from Southampton General Hospital, Ashya King begins treatment in Prague

Ashya King's prescribed treatment plan for proton therapy

A version of Ashya King's treatment plan using conventional radiation therapy

September 17, 2014 — Five-year-old Ashya King, the brain tumor patient whose case made headlines in Europe after his parents unlawfully took him from his hospital in Southampton, England, against the advice of doctors, began undergoing his prescribed treatment plan for proton therapy this week.

King was previously under the care of Southampton General Hospital for treatment of medulloblastoma. After unsatisfaction with the hospital’s treatment plan, King’s father sought more effective approaches through the Internet and came upon proton therapy. When the hospital refused to attempt it on King, his parents fled the United Kingdom to find a hospital that would, sparking a controversial debate.

The boy is now under the care of Motol University Hospital, where he is staying while undergoing treatment at the Proton Therapy Centre Czech in Prague. The overall course of treatment will take place over 30 visits; the first 13 will be to deliver irradiation to the entire tumor area—including the spinal cord, to ensure it is not spreading via cerebrospinal fluid—while the following 17 will be to treat just the tumor volume.

“There is a 70 to 80 percent survival rate for the condition such as the one Ashya has, and there is now every reason to hope that he will make a full recovery,” said his attending physician, Barbora Ondrová, M.D.

To illustrate the differences between proton therapy and conventional radiation therapy, the specialists at Proton Therapy Centre Czech drew up treatment plans for both techniques. In King’s case, it is necessary to apply the highest possible dose into the tumor but protect the tissue around it as much as possible. Vital structures to be protected include the heart, lung, liver and intestines. This means decreasing the risk of developing cardiovascular disorders, breathing disorders or metabolic disorders, and better protection of the swallowing functions and normal food intake.

For more information:

Related Content

ASTRO and ASCO Launch New Cancer Care Quality Registry
News | Radiation Therapy | January 22, 2018
January 22, 2018 — A registry that tracks the quality of medical care provided to patients receiving cancer treatment
First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
Overlay Init